Cargando…

Tofacitinib fails to prevent T cell transfer colitis in mice but ameliorates disease activity

Tofactinib is a JAK inhibitor approved for ulcerative colitis in humans. Despite of its’ proven effectiveness in humans, mechanistic data are scarce on the effectiveness of Tofactinib in experimental colitis in mice. We induced experimental colitis by transfer of CD4+CD25− isolated T cells into RAG2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Subramanyam, Sudheendra Hebbar, Hriczko, Judit Turyne, Pappas, Angeliki, Schippers, Angela, Wagner, Nobert, Ohl, Kim, Tenbrock, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9992375/ https://www.ncbi.nlm.nih.gov/pubmed/36882462 http://dx.doi.org/10.1038/s41598-023-30616-w

Ejemplares similares

Pediatric IBD patients show medication and disease activity dependent changes in NK cell and CD4 memory T cell populations
por: Pappa, Angeliki, et al.
Publicado: (2023)

NRF2/Itaconate Axis Regulates Metabolism and Inflammatory Properties of T Cells in Children with JIA
por: Rajendiran, Anandhi, et al.
Publicado: (2022)

CD11c-Specific Deletion Reveals CREB as a Critical Regulator of DC Function during the Germinal Center Response
por: Ohl, Kim, et al.
Publicado: (2018)

CREM Alpha Enhances IL-21 Production in T Cells In Vivo and In Vitro
por: Ohl, Kim, et al.
Publicado: (2016)

Initiation of LPS-induced pulmonary dysfunction and its recovery occur independent of T cells
por: Verjans, Eva, et al.
Publicado: (2018)

β7-Integrin exacerbates experimental DSS-induced colitis in mice by directing inflammatory monocytes into the colon
por: Schippers, A, et al.
Publicado: (2016)

Inflammatory Cytokines in Systemic Lupus Erythematosus
por: Ohl, Kim, et al.
Publicado: (2011)

Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression
por: Ohl, Kim, et al.
Publicado: (2018)

Oxidative Stress in SLE T Cells, Is NRF2 Really the Target to Treat?
por: Ohl, Kim, et al.
Publicado: (2021)

The transcription factor CREM drives an inflammatory phenotype of T cells in oligoarticular juvenile idiopathic arthritis
por: Ohl, Kim, et al.
Publicado: (2018)

The role and prospect of tofacitinib in patients with ulcerative colitis
por: Lee, Jun
Publicado: (2023)

Amelioration of unstable vitiligo and normalization of thryroglobulin antibodies with oral tofacitinib
por: Moore, Angela Yen, et al.
Publicado: (2022)

Oxidative stress in multiple sclerosis: Central and peripheral mode of action
por: Ohl, Kim, et al.
Publicado: (2016)

Dysregulated neutrophilic cell death in SLE: a spotlight on ferroptosis
por: Ohl, Kim, et al.
Publicado: (2021)

Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis
por: Wang, Wenfei, et al.
Publicado: (2019)

New Insights in Immunometabolism in Neonatal Monocytes and Macrophages in Health and Disease
por: de Jong, Renske, et al.
Publicado: (2023)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
por: Loftus, Edward V, et al.
Publicado: (2022)

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2018)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Review article: guide to tofacitinib dosing in patients with ulcerative colitis
por: Irving, Peter M., et al.
Publicado: (2022)

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2021)

Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
por: Long, Millie D, et al.
Publicado: (2022)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Transcription factor motif enrichment in whole transcriptome analysis identifies STAT4 and BCL6 as the most prominent binding motif in systemic juvenile idiopathic arthritis
por: Hügle, Boris, et al.
Publicado: (2018)

Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
por: Paschos, Paschalis, et al.
Publicado: (2018)

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
por: Sandborn, William J., et al.
Publicado: (2019)

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022)

Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis
por: Bodryagina, Evgenia, et al.
Publicado: (2022)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Fulminant Demodex folliculitis in a patient with ulcerative colitis treated with tofacitinib
por: Neudorfer, Carolina, et al.
Publicado: (2023)

Nrf2 Is a Central Regulator of Metabolic Reprogramming of Myeloid-Derived Suppressor Cells in Steady State and Sepsis
por: Ohl, Kim, et al.
Publicado: (2018)

The JAK inhibitor tofacitinib ameliorates immune-mediated liver injury in mice
por: Wang, Han, et al.
Publicado: (2019)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data
por: Varyani, Fumi, et al.
Publicado: (2019)

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
por: Shimizu, Hiromichi, et al.
Publicado: (2021)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Effects of Dextran Sulfate Sodium-Induced Ulcerative Colitis on the Disposition of Tofacitinib in Rats
por: Bae, Sung Hun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ofd767bp85v2jk4rig30bhkfes